These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35448201)

  • 21. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
    O'Brien SM
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):636-638. PubMed ID: 34637429
    [No Abstract]   [Full Text] [Related]  

  • 24. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
    Eyre TA; Roeker LE; Fox CP; Gohill SH; Walewska R; Walter HS; Forconi F; Broom A; Arumainathan A; Brander DM; Allan JN; Schuster SJ; Hill BT; Lansigan F; Cheson BD; Lamanna N; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Pearson L; Pagel JM; Jacobs R; Mato AR
    Br J Haematol; 2020 Mar; 188(6):918-923. PubMed ID: 31682002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
    Lu P; Wang S; Franzen CA; Venkataraman G; McClure R; Li L; Wu W; Niu N; Sukhanova M; Pei J; Baldwin DA; Nejati R; Wasik MA; Khan N; Tu Y; Gao J; Chen Y; Ma S; Larson RA; Wang YL
    Blood Cancer J; 2021 Feb; 11(2):39. PubMed ID: 33602908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
    Levin MD; Kater AP; Mattsson M; Kersting S; Ranti J; Thi Tuyet Tran H; Nasserinejad K; Niemann CU
    BMJ Open; 2020 Oct; 10(10):e039168. PubMed ID: 33060089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
    Barr PM; Tedeschi A; Wierda WG; Allan JN; Ghia P; Vallisa D; Jacobs R; O'Brien S; Grigg AP; Walker P; Zhou C; Ninomoto J; Krigsfeld G; Tam CS
    Clin Cancer Res; 2022 Oct; 28(20):4385-4391. PubMed ID: 35939599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.
    Pozzi S; Potenza L; Giusti D; Colaci E; Pioli V; Leonardi G; Maccaferri M; Luppi M; Marasca R
    Am J Case Rep; 2022 Aug; 23():e935941. PubMed ID: 36016481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
    Ye CJ; Xu WB; Yu Q; Wu C; Huang L; Li JM; Yan H
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):700-702. PubMed ID: 31495144
    [No Abstract]   [Full Text] [Related]  

  • 32. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
    Tang X; Zou W; Peng P; Bai Y
    Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL.
    Rogers KA
    Clin Cancer Res; 2020 Jul; 26(14):3501-3502. PubMed ID: 32366672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Rogers KA; Huang Y; Ruppert AS; Abruzzo LV; Andersen BL; Awan FT; Bhat SA; Dean A; Lucas M; Banks C; Grantier C; Heerema NA; Lozanski G; Maddocks KJ; Valentine TR; Weiss DM; Jones JA; Woyach JA; Byrd JC
    J Clin Oncol; 2020 Nov; 38(31):3626-3637. PubMed ID: 32795224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
    Jain N; Gandhi V; Wierda W
    N Engl J Med; 2019 Aug; 381(8):789. PubMed ID: 31433937
    [No Abstract]   [Full Text] [Related]  

  • 36. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
    Bonfiglio S; Sutton LA; Ljungström V; Capasso A; Pandzic T; Weström S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bödör C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Österborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfò L; Rosenquist R; Ghia P
    Blood Adv; 2023 Jun; 7(12):2794-2806. PubMed ID: 36696464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
    Kater AP; Slinger E; Cretenet G; Martens AW; Balasubramanian S; Leverson JD; Eldering E
    Blood Adv; 2021 Dec; 5(23):5410-5414. PubMed ID: 34555843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
    Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
    Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on the CAPTIVATE trial of ibrutinib plus venetoclax.
    Siddiqi T
    Clin Adv Hematol Oncol; 2023 Dec; 21(12):654-657. PubMed ID: 38039059
    [No Abstract]   [Full Text] [Related]  

  • 40. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.